TL;DR
This study investigates the traditional Chinese medicine decoction, Qi Yin San Liang San (QYSLS), for treating skin adverse reactions caused by EGFR inhibitors (EGFRIs). Using network pharmacology and in vitro experiments, they identified luteolin and quercetin as key active compounds that target PTGS2, MMP9, and CCL2, modulating the IL-17 and TNF signaling pathways to alleviate these side effects.
What Problem Does This Paper Address?
Epidermal growth factor receptor inhibitors (EGFRIs) are crucial in treating certain cancers, particularly non-small cell lung cancer. However, a significant and common side effect is the development of adverse skin reactions, most notably rash. These reactions can be severe, impacting patient quality of life and sometimes forcing treatment discontinuation. While some treatments exist, they are often unsatisfactory, leading to a need for safer and more effective alternatives. Traditional Chinese Medicine (TCM) offers a promising avenue, with QYSLS being a folk prescription already in clinical use for EGFRI-induced skin reactions. However, the precise molecular mechanisms underlying QYSLS's therapeutic effects remained unclear, prompting this investigation.
Methods
The researchers employed a multi-pronged approach combining in vivo, network pharmacology, and in vitro experiments:
- In Vivo Validation: They first established a mouse model of EGFRI-induced adverse skin reactions using gefitinib and then treated these mice with varying doses of QYSLS to assess its efficacy in reducing skin side effects and improving organ indices.
- Network Pharmacology:
- Target Identification: They identified genes associated with EGFRI-related adverse skin reactions by analyzing data from the Gene Expression Omnibus (GEO) database.
- Compound and Target Prediction: Effective components of QYSLS and their potential targets were predicted using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) and Batman-TCM databases.
- Network Construction: Protein-protein interaction (PPI) networks were built using STRING and visualized with Cytoscape to identify core targets.
- Pathway Analysis: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using Bioconductor to understand the biological processes and signaling pathways involved.
- Molecular Docking: This technique was used to verify the binding affinity between predicted active compounds and identified key targets.
- In Vitro Experiments: The findings from network pharmacology were validated using human keratinocyte (HaCaT) cells. They examined the effects of gefitinib and key QYSLS compounds (luteolin, quercetin, licochalcone a, and kaempferol) on cell viability and the mRNA expression of specific target genes (PTGS2, MMP9, and CCL2) using CCK-8 assays and qPCR.
Datasets
- Gene Expression Omnibus (GEO) Database: Specifically, the GSE74407 dataset was used to identify differentially expressed genes related to EGFRI-induced adverse skin reactions.
- Traditional Chinese Medicine Systems Pharmacology (TCMSP) Database: Used for identifying effective components and their targets within QYSLS.
- Batman-TCM Database: Used to collect information on active ingredients from centipede, a component of QYSLS.
- STRING Database: Utilized for constructing protein-protein interaction networks.
- RCSB PDB Database: Used to obtain crystal structures of hub protein targets for molecular docking.
Key Insights and Ideas
- Multi-Target, Multi-Pathway Approach of TCM: The study reinforces the understanding that TCM therapies, like QYSLS, often exert their effects through complex interactions with multiple targets and pathways, a stark contrast to single-target Western pharmaceuticals.
- Identification of Key Active Compounds: The research pinpoints luteolin and quercetin as the primary active ingredients in QYSLS responsible for mitigating EGFRI-related skin reactions. This provides a focus for future research and potential drug development.
- Crucial Role of IL-17 and TNF Pathways: The study highlights the IL-17 and TNF signaling pathways as central to the pathogenesis of EGFRI-induced skin reactions and, consequently, as key targets for QYSLS intervention.
- Specific Target Genes Identified: The identification of PTGS2, MMP9, and CCL2 as critical targets provides concrete molecular mechanisms for QYSLS's action.
Key Results
- In Vivo Efficacy: QYSLS treatment significantly reduced the occurrence and severity of skin side effects in a gefitinib-induced mouse model, also improving liver and spleen indices.
- Network Pharmacology Findings: Identified luteolin, quercetin, licochalcone a, and kaempferol as active compounds and PTGS2, MMP9, and CCL2 as key targets, strongly linked to the IL-17 and TNF signaling pathways.
- Molecular Docking: Confirmed good binding interactions between luteolin, quercetin, kaempferol, and licochalcone a with PTGS2, CCL2, and MMP9.
- In Vitro Validation:
- Luteolin and quercetin demonstrated a protective effect on HaCaT cells, reversing the inhibitory effect of gefitinib on cell proliferation.
- Luteolin and quercetin modulated the mRNA expression of PTGS2, MMP9, and CCL2 in HaCaT cells treated with gefitinib, with luteolin and quercetin decreasing PTGS2 and MMP9 expression and increasing CCL2 expression.
Limitations and Future Work
- Further Pathway Exploration: While the IL-17 and TNF pathways were identified, the precise mechanisms by which TNF influences Th differentiation and promotes IL-17 production require further investigation.
- Individual Drug Efficacy: The paper notes that while Lonicera japonica, licorice, and Astragalus membranaceus are components of QYSLS, their individual anti-inflammatory contributions warrant further study.
- In Vivo vs. In Vitro Discrepancies: The paper notes that luteolin and quercetin increased PTGS2 and MMP9 expression and decreased CCL2 in vitro, which contrasts with the general understanding of these targets in inflammation. This discrepancy warrants further investigation.
- Clinical Translation: While QYSLS is used clinically, further large-scale clinical trials would be beneficial to solidify its efficacy and safety profile for EGFRI-related skin reactions.
Summary updated